(%)
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
- Ownership
-
Dynavax Technologies Corporation Executive Compensation
* In original currency USD
Loading Data
|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total Amount |
|---|---|---|---|---|---|---|---|---|
| Thursday, April 11th, 2024 | 2021 | Ryan Spencer Chief Executive Officer and Director | 600,000 | 0 | 1,605,608 | 588,000 | 5,431 | 4,519,489 |
| Thursday, April 11th, 2024 | 2023 | Ryan Spencer Chief Executive Officer and Director | 760,000 | 0 | 2,281,250 | 712,500 | 13,686 | 5,810,736 |
| Thursday, April 11th, 2024 | 2022 | Ryan Spencer Chief Executive Officer and Director | 695,000 | 0 | 1,522,500 | 544,880 | 11,355 | 5,594,000 |
| Thursday, April 11th, 2024 | 2023 | David F. Novack President and Chief Operating Officer | 570,296 | 0 | 885,125 | 427,722 | 15,563 | 2,993,331 |
| Thursday, April 11th, 2024 | 2022 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 425,000 | 0 | 389,760 | 240,550 | 8,716 | 1,793,266 |
| Thursday, April 11th, 2024 | 2022 | David F. Novack President and Chief Operating Officer | 545,738 | 0 | 645,540 | 366,736 | 13,124 | 2,779,823 |
| Thursday, April 11th, 2024 | 2021 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 480,938 | 0 | 534,300 | 329,443 | 6,793 | 1,925,564 |
| Thursday, April 11th, 2024 | 2022 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 500,176 | 0 | 316,680 | 277,598 | 11,983 | 1,710,780 |
| Thursday, April 11th, 2024 | 2023 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 521,434 | 0 | 438,000 | 325,896 | 14,193 | 1,883,323 |
| Thursday, April 11th, 2024 | 2021 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 312,500 | 15,000 | 0 | 221,875 | 4,042 | 2,804,337 |
| Thursday, April 11th, 2024 | 2023 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 475,000 | 0 | 547,500 | 301,625 | 11,930 | 2,065,805 |
| Thursday, April 11th, 2024 | 2021 | David F. Novack President and Chief Operating Officer | 519,750 | 0 | 935,025 | 436,590 | 13,635 | 2,918,100 |
| Thursday, April 13th, 2023 | 2022 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 500,176 | 0 | 316,680 | 277,598 | 11,983 | 1,710,780 |
| Thursday, April 13th, 2023 | 2020 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 466,930 | 0 | 135,500 | 256,345 | 2,000 | 1,242,671 |
| Thursday, April 13th, 2023 | 2022 | Ryan Spencer Chief Executive Officer and Director | 695,000 | 0 | 1,522,500 | 544,880 | 11,355 | 5,594,000 |
| Thursday, April 13th, 2023 | 2021 | Ryan Spencer Chief Executive Officer and Director | 600,000 | 0 | 1,605,608 | 588,000 | 5,431 | 4,519,489 |
| Thursday, April 13th, 2023 | 2020 | Ryan Spencer Chief Executive Officer and Director | 515,000 | 0 | 206,451 | 342,990 | 2,000 | 1,521,779 |
| Thursday, April 13th, 2023 | 2022 | David F. Novack President and Chief Operating Officer | 545,738 | 0 | 645,540 | 366,736 | 13,124 | 2,779,823 |
| Thursday, April 13th, 2023 | 2021 | David F. Novack President and Chief Operating Officer | 519,750 | 0 | 935,025 | 436,590 | 13,635 | 2,918,100 |
| Thursday, April 13th, 2023 | 2020 | David F. Novack President and Chief Operating Officer | 495,000 | 0 | 189,700 | 302,198 | 2,000 | 1,512,640 |
| Thursday, April 13th, 2023 | 2022 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 425,000 | 0 | 389,760 | 240,550 | 8,716 | 1,793,266 |
| Thursday, April 13th, 2023 | 2021 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 312,500 | 15,000 | 0 | 221,875 | 4,042 | 2,804,337 |
| Thursday, April 13th, 2023 | 2021 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President | 480,938 | 0 | 534,300 | 329,443 | 6,793 | 1,925,564 |
| Thursday, April 14th, 2022 | 2020 | Ryan Spencer Chief Executive Officer and Director | 515,000 | 0 | 206,451 | 342,990 | 2,000 | 1,521,779 |
| Thursday, April 14th, 2022 | 2020 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 466,930 | 0 | 135,500 | 256,345 | 2,000 | 1,242,671 |
| Thursday, April 14th, 2022 | 2019 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 450,872 | 0 | 230,340 | 209,665 | 2,000 | 1,504,310 |
| Thursday, April 14th, 2022 | 2020 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 464,398 | 0 | 135,500 | 254,955 | 2,000 | 1,238,749 |
| Thursday, April 14th, 2022 | 2021 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 77,626 | 0 | 534,300 | 0 | 650,711 | 1,994,399 |
| Thursday, April 14th, 2022 | 2021 | Kelly MacDonald Senior Vice President and Chief Financial Officer | 312,500 | 15,000 | 0 | 221,875 | 4,042 | 2,804,337 |
| Thursday, April 14th, 2022 | 2019 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 453,330 | 0 | 272,220 | 210,798 | 2,000 | 1,660,950 |
| Thursday, April 14th, 2022 | 2020 | David F. Novack President and Chief Operating Officer | 495,000 | 0 | 189,700 | 302,198 | 2,000 | 1,512,640 |
| Thursday, April 14th, 2022 | 2019 | David F. Novack President and Chief Operating Officer | 465,886 | 0 | 272,220 | 229,382 | 2,000 | 2,670,850 |
| Thursday, April 14th, 2022 | 2021 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 480,938 | 0 | 534,300 | 329,443 | 6,793 | 1,925,564 |
| Thursday, April 14th, 2022 | 2021 | David F. Novack President and Chief Operating Officer | 519,750 | 0 | 935,025 | 436,590 | 13,635 | 2,918,100 |
| Thursday, April 14th, 2022 | 2019 | Ryan Spencer Chief Executive Officer and Director | 391,212 | 0 | 654,375 | 152,375 | 2,000 | 3,157,482 |
| Thursday, April 14th, 2022 | 2021 | Ryan Spencer Chief Executive Officer and Director | 600,000 | 0 | 1,605,608 | 588,000 | 5,431 | 4,519,489 |
| Friday, April 16th, 2021 | 2020 | David F. Novack President and Chief Operating Officer | 495,000 | 0 | 189,700 | 302,198 | 2,000 | 1,512,640 |
| Friday, April 16th, 2021 | 2018 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 438,000 | 0 | 0 | 216,810 | 2,000 | 1,739,810 |
| Friday, April 16th, 2021 | 2019 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 453,330 | 0 | 272,220 | 210,798 | 2,000 | 1,660,950 |
| Friday, April 16th, 2021 | 2020 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 466,930 | 0 | 135,500 | 256,345 | 2,000 | 1,242,671 |
| Friday, April 16th, 2021 | 2018 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 439,875 | 0 | 0 | 216,639 | 2,000 | 3,562,514 |
| Friday, April 16th, 2021 | 2019 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 450,872 | 0 | 230,340 | 209,665 | 2,000 | 1,504,310 |
| Friday, April 16th, 2021 | 2020 | Michael S. Ostrach Former Senior Vice President, Chief Financial Officer and Chief Business Officer | 464,398 | 0 | 135,500 | 254,955 | 2,000 | 1,238,749 |
| Friday, April 16th, 2021 | 2018 | David F. Novack President and Chief Operating Officer | 401,700 | 0 | 0 | 210,892 | 2,000 | 1,697,592 |
| Friday, April 16th, 2021 | 2019 | Ryan Spencer Chief Executive Officer and Director | 391,212 | 0 | 654,375 | 152,375 | 2,000 | 3,157,482 |
| Friday, April 16th, 2021 | 2020 | Ryan Spencer Chief Executive Officer and Director | 515,000 | 0 | 206,451 | 342,990 | 2,000 | 1,521,779 |
| Friday, April 16th, 2021 | 2019 | David F. Novack President and Chief Operating Officer | 465,886 | 0 | 272,220 | 229,382 | 2,000 | 2,670,850 |
| Friday, April 17th, 2020 | 2019 | Eddie Gray Former Chief Executive Officer and Director | 375,795 | 0 | 732,900 | 0 | 3,727,518 | 9,227,662 |
| Friday, April 17th, 2020 | 2018 | Eddie Gray Former Chief Executive Officer and Director | 621,000 | 0 | 0 | 335,340 | 2,000 | 4,748,840 |
| Friday, April 17th, 2020 | 2018 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 439,875 | 0 | 0 | 216,639 | 2,000 | 3,562,514 |
| Friday, April 17th, 2020 | 2019 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 453,330 | 0 | 272,220 | 210,798 | 2,000 | 1,660,950 |
| Friday, April 17th, 2020 | 2018 | David F. Novack President and Chief Operating Officer | 401,700 | 0 | 0 | 210,892 | 2,000 | 1,697,592 |
| Friday, April 17th, 2020 | 2018 | Robert Janssen, M.D. Senior Vice President and Chief Medical Officer | 438,000 | 0 | 0 | 216,810 | 2,000 | 1,739,810 |
| Friday, April 17th, 2020 | 2019 | Robert L. Coffman, Ph.D. Former Senior Vice President and Chief Scientific Officer | 455,849 | 0 | 230,340 | 0 | 522,791 | 1,830,387 |
| Friday, April 17th, 2020 | 2018 | Robert L. Coffman, Ph.D. Former Senior Vice President and Chief Scientific Officer | 483,134 | 0 | 0 | 239,151 | 2,000 | 3,628,285 |
| Friday, April 17th, 2020 | 2019 | David F. Novack President and Chief Operating Officer | 465,886 | 0 | 272,220 | 229,382 | 2,000 | 2,670,850 |
| Friday, April 17th, 2020 | 2019 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 450,872 | 0 | 230,340 | 209,665 | 2,000 | 1,504,310 |
| Friday, April 17th, 2020 | 2019 | Ryan Spencer Chief Executive Officer and Director | 391,212 | 0 | 654,375 | 152,375 | 2,000 | 3,157,482 |
| Monday, April 22nd, 2019 | 2018 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 439,875 | 0 | 0 | 216,639 | 2,000 | 3,562,514 |
| Monday, April 22nd, 2019 | 2017 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 1,126,060 | 265,625 | 2,000 | 1,818,685 |
| Monday, April 22nd, 2019 | 2018 | David F. Novack Senior Vice President, Operations and Quality | 401,700 | 0 | 0 | 210,893 | 2,000 | 1,697,593 |
| Monday, April 22nd, 2019 | 2017 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 1,223,041 | 297,582 | 2,000 | 1,989,419 |
| Monday, April 22nd, 2019 | 2016 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 0 | 0 | 2,000 | 1,172,548 |
| Monday, April 22nd, 2019 | 2018 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 438,000 | 0 | 0 | 216,810 | 2,000 | 1,739,810 |
| Monday, April 22nd, 2019 | 2017 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 400,000 | 0 | 1,068,056 | 260,000 | 2,000 | 1,730,056 |
| Monday, April 22nd, 2019 | 2016 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 400,000 | 0 | 0 | 0 | 2,000 | 1,072,240 |
| Monday, April 22nd, 2019 | 2017 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 1,036,148 | 241,406 | 2,000 | 1,665,804 |
| Monday, April 22nd, 2019 | 2016 | Eddie Gray CEO and Director | 600,000 | 0 | 0 | 0 | 2,000 | 2,947,840 |
| Monday, April 22nd, 2019 | 2016 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 0 | 0 | 2,000 | 1,130,752 |
| Monday, April 22nd, 2019 | 2018 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 483,134 | 0 | 0 | 239,151 | 2,000 | 3,628,285 |
| Monday, April 22nd, 2019 | 2016 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 0 | 0 | 2,000 | 924,442 |
| Monday, April 22nd, 2019 | 2018 | Eddie Gray CEO and Director | 621,000 | 0 | 0 | 335,340 | 2,000 | 4,748,840 |
| Monday, April 22nd, 2019 | 2017 | Eddie Gray CEO and Director | 600,000 | 0 | 2,094,113 | 450,000 | 2,000 | 3,146,113 |
| Friday, April 20th, 2018 | 2016 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 0 | 0 | 2,000 | 1,172,548 |
| Friday, April 20th, 2018 | 2015 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 369,513 | 0 | 0 | 206,928 | 2,000 | 1,326,257 |
| Friday, April 20th, 2018 | 2016 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 400,000 | 0 | 0 | 0 | 2,000 | 1,072,240 |
| Friday, April 20th, 2018 | 2017 | Robert Janssen, M.D. Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs | 400,000 | 0 | 1,068,056 | 260,000 | 2,000 | 1,730,056 |
| Friday, April 20th, 2018 | 2015 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 453,200 | 0 | 0 | 253,792 | 2,000 | 2,009,623 |
| Friday, April 20th, 2018 | 2017 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 1,223,041 | 297,582 | 2,000 | 1,989,419 |
| Friday, April 20th, 2018 | 2015 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 390,000 | 0 | 0 | 228,150 | 2,000 | 2,040,503 |
| Friday, April 20th, 2018 | 2016 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 0 | 0 | 2,000 | 1,130,752 |
| Friday, April 20th, 2018 | 2017 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 1,036,148 | 241,406 | 2,000 | 1,665,804 |
| Friday, April 20th, 2018 | 2017 | Eddie Gray CEO and Director | 600,000 | 0 | 2,094,113 | 450,000 | 2,000 | 3,146,113 |
| Friday, April 20th, 2018 | 2016 | Eddie Gray CEO and Director | 600,000 | 0 | 0 | 0 | 2,000 | 2,947,840 |
| Friday, April 20th, 2018 | 2015 | Eddie Gray CEO and Director | 566,500 | 0 | 0 | 370,491 | 2,000 | 3,943,607 |
| Friday, April 20th, 2018 | 2017 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 1,126,060 | 265,625 | 2,000 | 1,818,685 |
| Friday, April 20th, 2018 | 2016 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 0 | 0 | 2,000 | 924,442 |
| Friday, April 20th, 2018 | 2015 | David F. Novack Senior Vice President, Operations and Quality | 375,000 | 0 | 0 | 210,000 | 2,000 | 1,588,539 |
| Friday, April 21st, 2017 | 2016 | Robert Janssen, M.D. Vice President and Chief Medical Officer | 400,000 | 0 | 0 | 0 | 2,000 | 1,072,240 |
| Friday, April 21st, 2017 | 2014 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 440,000 | 0 | 42,250 | 286,000 | 0 | 768,250 |
| Friday, April 21st, 2017 | 2015 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 453,200 | 0 | 0 | 253,792 | 2,000 | 2,009,623 |
| Friday, April 21st, 2017 | 2016 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 466,796 | 0 | 0 | 0 | 2,000 | 1,172,548 |
| Friday, April 21st, 2017 | 2014 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 354,152 | 0 | 181,000 | 221,345 | 0 | 1,181,828 |
| Friday, April 21st, 2017 | 2015 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 390,000 | 0 | 0 | 228,150 | 2,000 | 2,040,503 |
| Friday, April 21st, 2017 | 2016 | Michael S. Ostrach Senior Vice President, Chief Financial Officer, Chief Business Officer | 425,000 | 0 | 0 | 0 | 2,000 | 1,130,752 |
| Friday, April 21st, 2017 | 2014 | Eddie Gray CEO and Director | 515,000 | 0 | 855,000 | 432,600 | 0 | 5,367,509 |
| Friday, April 21st, 2017 | 2015 | Eddie Gray CEO and Director | 566,500 | 0 | 0 | 370,491 | 2,000 | 3,943,607 |
| Friday, April 21st, 2017 | 2016 | Eddie Gray CEO and Director | 600,000 | 0 | 0 | 0 | 2,000 | 2,947,840 |
| Friday, April 21st, 2017 | 2015 | David F. Novack Senior Vice President, Operations and Quality | 375,000 | 0 | 0 | 210,000 | 2,000 | 1,588,539 |
| Friday, April 21st, 2017 | 2016 | David F. Novack Senior Vice President, Operations and Quality | 386,250 | 0 | 0 | 0 | 2,000 | 924,442 |
| Friday, April 21st, 2017 | 2014 | Robert Janssen, M.D. Vice President and Chief Medical Officer | 358,750 | 0 | 181,000 | 246,641 | 0 | 1,069,945 |
| Friday, April 21st, 2017 | 2015 | Robert Janssen, M.D. Vice President and Chief Medical Officer | 369,513 | 0 | 0 | 206,928 | 2,000 | 1,326,257 |
| Friday, April 21st, 2017 | 2014 | David F. Novack Senior Vice President, Operations and Quality | 309,000 | 0 | 362,000 | 208,575 | 0 | 1,226,141 |
| Friday, April 22nd, 2016 | 2013 | Michael S. Ostrach Senior Vice President, Chief Financial Officer and Chief Business Officer | 342,176 | 0 | 0 | 185,000 | 3,616 | 1,092,752 |
| Friday, April 22nd, 2016 | 2013 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 282,620 | 0 | 0 | 175,000 | 250 | 963,634 |
| Friday, April 22nd, 2016 | 2014 | Eddie Gray CEO and Director | 515,000 | 0 | 855,000 | 432,600 | 0 | 5,367,509 |
| Friday, April 22nd, 2016 | 2013 | Eddie Gray CEO and Director | 333,333 | 200,000 | 0 | 50,000 | 200,250 | 3,813,583 |
| Friday, April 22nd, 2016 | 2015 | Robert Janssen, M.D. Chief Medical Officer and Vice President, Clinical Development | 369,513 | 0 | 0 | 206,928 | 2,000 | 1,326,257 |
| Friday, April 22nd, 2016 | 2014 | David F. Novack Senior Vice President, Operations and Quality | 309,000 | 0 | 362,000 | 208,575 | 0 | 1,226,141 |
| Friday, April 22nd, 2016 | 2013 | David F. Novack Senior Vice President, Operations and Quality | 230,769 | 75,000 | 0 | 155,000 | 1,932 | 1,049,801 |
| Friday, April 22nd, 2016 | 2014 | Robert Janssen, M.D. Chief Medical Officer and Vice President, Clinical Development | 358,750 | 0 | 181,000 | 246,641 | 0 | 1,069,945 |
| Friday, April 22nd, 2016 | 2013 | Robert Janssen, M.D. Chief Medical Officer and Vice President, Clinical Development | 323,878 | 0 | 175,500 | 145,000 | 4,361 | 648,739 |
| Friday, April 22nd, 2016 | 2015 | David F. Novack Senior Vice President, Operations and Quality | 375,000 | 0 | 0 | 210,000 | 2,000 | 1,588,539 |
| Friday, April 22nd, 2016 | 2015 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 453,200 | 0 | 0 | 253,792 | 2,000 | 2,009,623 |
| Friday, April 22nd, 2016 | 2014 | Michael S. Ostrach Senior Vice President, Chief Financial Officer and Chief Business Officer | 354,152 | 0 | 181,000 | 221,345 | 0 | 1,181,828 |
| Friday, April 22nd, 2016 | 2015 | Michael S. Ostrach Senior Vice President, Chief Financial Officer and Chief Business Officer | 390,000 | 0 | 0 | 228,150 | 2,000 | 2,040,503 |
| Friday, April 22nd, 2016 | 2015 | Eddie Gray CEO and Director | 566,500 | 0 | 0 | 370,491 | 2,000 | 3,943,607 |
| Friday, April 22nd, 2016 | 2014 | Robert L. Coffman, Ph.D. Senior Vice President and Chief Scientific Officer | 440,000 | 0 | 42,250 | 286,000 | 0 | 768,250 |
| Wednesday, April 25th, 2012 | 2010 | Dino Dina, M.D., Chief Executive Officer and Director | 408,000 | 0 | 0 | 195,840 | 23,661 | 841,641 |
| Wednesday, April 25th, 2012 | 2011 | Dino Dina, M.D., Chief Executive Officer and Director | 448,800 | 0 | 0 | 215,424 | 11,498 | 2,787,647 |
| Wednesday, April 25th, 2012 | 2009 | Dino Dina, M.D., Chief Executive Officer and Director | 408,000 | 0 | 0 | 244,800 | 9,631 | 758,611 |
| Wednesday, April 20th, 2011 | 2009 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 305,000 | 0 | 0 | 152,500 | 3,947 | 497,515 |
| Wednesday, April 20th, 2011 | 2009 | Jennifer Lew Vice President, Finance | 200,625 | 0 | 0 | 68,063 | 130 | 280,841 |
| Wednesday, April 20th, 2011 | 2010 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 321,829 | 0 | 0 | 147,315 | 5,454 | 617,358 |
| Wednesday, April 20th, 2011 | 2008 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 281,112 | 0 | 78,600 | 118,067 | 3,511 | 715,215 |
| Wednesday, April 20th, 2011 | 2008 | Dino Dina, M.D. Chief Executive Officer and Director | 408,000 | 0 | 117,900 | 146,880 | 2,538 | 1,034,438 |
| Wednesday, April 20th, 2011 | 2010 | Stephen F. Tuck, Ph.D. | 51,875 | 50,000 | 148,500 | 0 | 544,148 | 1,056,058 |
| Wednesday, April 20th, 2011 | 2010 | Dino Dina, M.D. Chief Executive Officer and Director | 408,000 | 0 | 0 | 195,840 | 16,843 | 834,823 |
| Wednesday, April 20th, 2011 | 2009 | Dino Dina, M.D. Chief Executive Officer and Director | 408,000 | 0 | 0 | 244,800 | 1,660 | 750,640 |
| Wednesday, April 20th, 2011 | 2010 | Jennifer Lew Vice President, Finance | 214,200 | 0 | 0 | 68,544 | 1,644 | 355,768 |
| Wednesday, April 20th, 2011 | 2010 | J. Tyler Martin, M.D. | 383,000 | 0 | 0 | 157,641 | 13,808 | 1,429,212 |
| Tuesday, November 30th, 2010 | 2007 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 300,000 | 0 | 0 | 105,600 | 2,079 | 407,679 |
| Tuesday, November 30th, 2010 | 2009 | Jennifer Lew Vice President, Finance | 200,625 | 0 | 0 | 68,063 | 4,242 | 284,953 |
| Tuesday, November 30th, 2010 | 2007 | Dino Dina, M.D. President, Chief Executive Officer and Director | 400,000 | 0 | 0 | 180,000 | 2,180 | 1,608,605 |
| Tuesday, November 30th, 2010 | 2009 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 305,000 | 0 | 0 | 152,500 | 19,687 | 513,255 |
| Tuesday, November 30th, 2010 | 2009 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 0 | 244,800 | 9,631 | 758,611 |
| Tuesday, November 30th, 2010 | 2008 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 117,900 | 146,880 | 2,538 | 1,034,438 |
| Tuesday, November 30th, 2010 | 2008 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 281,112 | 0 | 78,600 | 118,067 | 3,511 | 715,215 |
| Tuesday, November 30th, 2010 | 2007 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 275,600 | 0 | 0 | 103,626 | 4,787 | 548,241 |
| Tuesday, November 30th, 2010 | 2009 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 341,405 | 0 | 0 | 99,007 | 22,946 | 477,785 |
| Tuesday, November 30th, 2010 | 2008 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 360,184 | 0 | 0 | 124,081 | 20,741 | 582,099 |
| Tuesday, November 30th, 2010 | 2007 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 324,409 | 0 | 0 | 81,751 | 18,811 | 424,971 |
| Tuesday, November 30th, 2010 | 2009 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 0 | 153,500 | 32,318 | 528,886 |
| Tuesday, November 30th, 2010 | 2008 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 78,600 | 110,520 | 3,126 | 624,006 |
| Friday, March 26th, 2010 | 2007 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 324,409 | 0 | 0 | 81,751 | 18,811 | 424,971 |
| Friday, March 26th, 2010 | 2008 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 360,184 | 0 | 0 | 124,081 | 20,741 | 582,099 |
| Friday, March 26th, 2010 | 2009 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 341,405 | 0 | 0 | 99,007 | 22,946 | 477,785 |
| Friday, March 26th, 2010 | 2007 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 275,600 | 0 | 0 | 103,626 | 4,787 | 548,241 |
| Friday, March 26th, 2010 | 2008 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 281,112 | 0 | 78,600 | 118,067 | 3,511 | 715,215 |
| Friday, March 26th, 2010 | 2009 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 305,000 | 0 | 0 | 152,500 | 19,687 | 513,255 |
| Friday, March 26th, 2010 | 2009 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 0 | 153,500 | 32,318 | 528,886 |
| Friday, March 26th, 2010 | 2008 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 78,600 | 110,520 | 3,126 | 624,006 |
| Friday, March 26th, 2010 | 2007 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 300,000 | 0 | 0 | 105,600 | 2,079 | 407,679 |
| Friday, March 26th, 2010 | 2008 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 117,900 | 146,880 | 2,538 | 1,034,438 |
| Friday, March 26th, 2010 | 2007 | Dino Dina, M.D. President, Chief Executive Officer and Director | 400,000 | 0 | 0 | 180,000 | 2,180 | 1,608,605 |
| Friday, March 26th, 2010 | 2009 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 0 | 244,800 | 9,631 | 758,611 |
| Friday, March 26th, 2010 | 2009 | Jennifer Lew Vice President, Finance | 200,625 | 0 | 0 | 68,063 | 4,242 | 284,953 |
| Friday, April 3rd, 2009 | 2008 | Deborah A. Smeltzer Chief Financial Officer and Vice President, Operations | 308,550 | 0 | 3,992 | 111,078 | 250 | 797,909 |
| Friday, April 3rd, 2009 | 2007 | Dino Dina, M.D. President, Chief Executive Officer and Director | 400,000 | 0 | 0 | 180,000 | 2,180 | 1,611,913 |
| Friday, April 3rd, 2009 | 2006 | Deborah A. Smeltzer Chief Financial Officer and Vice President, Operations | 275,000 | 0 | 0 | 98,450 | 250 | 640,504 |
| Friday, April 3rd, 2009 | 2006 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 265,000 | 0 | 0 | 94,870 | 3,158 | 585,915 |
| Friday, April 3rd, 2009 | 2008 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 307,000 | 0 | 3,992 | 110,520 | 3,126 | 756,403 |
| Friday, April 3rd, 2009 | 2007 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 300,000 | 0 | 0 | 105,600 | 2,079 | 696,148 |
| Friday, April 3rd, 2009 | 2008 | Dino Dina, M.D. President, Chief Executive Officer and Director | 408,000 | 0 | 5,987 | 146,880 | 2,538 | 1,089,305 |
| Friday, April 3rd, 2009 | 2007 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 324,409 | 0 | 0 | 81,751 | 18,811 | 589,945 |
| Friday, April 3rd, 2009 | 2008 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 360,184 | 0 | 0 | 124,081 | 20,741 | 687,528 |
| Friday, April 3rd, 2009 | 2007 | Deborah A. Smeltzer Chief Financial Officer and Vice President, Operations | 302,500 | 0 | 0 | 108,900 | 188 | 754,870 |
| Friday, April 3rd, 2009 | 2008 | Martin E. Sanders, M.D. | 419,811 | 0 | 0 | 0 | 188 | 765,379 |
| Friday, April 3rd, 2009 | 2006 | Dino Dina, M.D. President, Chief Executive Officer and Director | 360,000 | 0 | 0 | 148,500 | 250 | 1,321,431 |
| Friday, April 3rd, 2009 | 2008 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 281,112 | 0 | 3,992 | 118,067 | 3,511 | 634,176 |
| Friday, April 3rd, 2009 | 2007 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 275,600 | 0 | 0 | 103,626 | 4,787 | 594,668 |
| Friday, April 25th, 2008 | 2007 | Zbigniew Janowicz, Ph.D. Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) | 324,409 | 0 | 0 | 81,751 | 18,811 | 589,945 |
| Friday, April 25th, 2008 | 2007 | Robert L. Coffman, Ph.D. Vice President and Chief Scientific Officer | 275,600 | 0 | 0 | 103,626 | 4,787 | 594,668 |
| Friday, April 25th, 2008 | 2007 | Michael S. Ostrach Vice President, Chief Business Officer and General Counsel | 300,000 | 0 | 0 | 105,600 | 2,079 | 696,148 |
| Friday, April 25th, 2008 | 2007 | Deborah A. Smeltzer Chief Financial Officer and Vice President, Operations | 302,500 | 0 | 0 | 108,900 | 188 | 754,870 |
| Friday, April 25th, 2008 | 2007 | Dino Dina, M.D. President, Chief Executive Officer and Director | 400,000 | 0 | 0 | 180,000 | 2,180 | 1,611,913 |
| Thursday, April 26th, 2007 | 2006 | President, Chief Executive Officer and Director Deborah A. Smeltzer, | 360,000 | 0 | 0 | 148,500 | 3,244 | 1,324,425 |
| Thursday, April 26th, 2007 | 2006 | Chief Financial Officer and Vice President, Operations Robert L. Coffman, Ph.D. | 275,000 | 0 | 0 | 98,450 | 250 | 640,504 |
| Thursday, April 26th, 2007 | 2006 | Vice President and Chief Scientific Officer Stephen F. Tuck, Ph.D. | 265,000 | 0 | 0 | 94,870 | 3,158 | 585,915 |
| Thursday, April 26th, 2007 | 2006 | Vice President, Biopharmaceutical Development Gary A. Van Nest, Ph.D. | 240,000 | 0 | 0 | 85,920 | 486 | 533,266 |
| Thursday, April 26th, 2007 | 2006 | Vice President, Preclinical Research | 230,000 | 0 | 0 | 82,340 | 3,248 | 480,604 |
| Friday, April 28th, 2006 | 2005 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 250,000 | 112,000 | 0 | 0 | 0 | 362,000 |
| Friday, April 28th, 2006 | 2003 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 120,000 | 0 | 0 | 0 | 420,000 |
| Friday, April 28th, 2006 | 2003 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 218,500 | 65,550 | 0 | 0 | 0 | 284,050 |
| Friday, April 28th, 2006 | 2004 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 250,000 | 100,000 | 0 | 0 | 0 | 350,000 |
| Friday, April 28th, 2006 | 2005 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 220,000 | 99,000 | 0 | 0 | 0 | 319,000 |
| Friday, April 28th, 2006 | 2004 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 212,500 | 85,000 | 0 | 0 | 0 | 297,500 |
| Friday, April 28th, 2006 | 2003 | Deborah A. Smeltzer Vice President, Operations and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Friday, April 28th, 2006 | 2003 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 104,166 | 0 | 0 | 0 | 0 | 104,166 |
| Friday, April 28th, 2006 | 2003 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| Friday, April 28th, 2006 | 2003 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| Friday, April 28th, 2006 | 2005 | Dino Dina, M.D. President and Chief Executive Officer and Director | 338,000 | 162,240 | 0 | 0 | 0 | 500,240 |
| Friday, April 28th, 2006 | 2004 | Dino Dina, M.D. President and Chief Executive Officer and Director | 325,000 | 130,000 | 0 | 0 | 0 | 455,000 |
| Friday, April 28th, 2006 | 2004 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 240,000 | 96,000 | 0 | 0 | 0 | 336,000 |
| Friday, April 28th, 2006 | 2005 | Deborah A. Smeltzer Vice President, Operations and Chief Financial Officer | 258,167 | 166,480 | 0 | 0 | 0 | 424,647 |
| Friday, April 28th, 2006 | 2004 | Deborah A. Smeltzer Vice President, Operations and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Friday, April 28th, 2006 | 2005 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 260,000 | 109,200 | 0 | 0 | 0 | 369,200 |
| Friday, April 28th, 2006 | 2005 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 220,000 | 99,000 | 0 | 0 | 0 | 319,000 |
| Friday, April 28th, 2006 | 2004 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 212,500 | 63,750 | 0 | 0 | 0 | 276,250 |
| Friday, April 29th, 2005 | 2004 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 212,500 | 63,750 | 0 | 0 | 0 | 276,250 |
| Friday, April 29th, 2005 | 2003 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| Friday, April 29th, 2005 | 2002 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 105,000 | 0 | 0 | 0 | 405,000 |
| Friday, April 29th, 2005 | 2002 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 180,000 | 54,000 | 0 | 0 | 0 | 234,000 |
| Friday, April 29th, 2005 | 2002 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 210,000 | 63,000 | 0 | 0 | 0 | 273,000 |
| Friday, April 29th, 2005 | 2002 | William J. Dawson Former Vice President, Finance Operations and Chief Financial Officer | 83,654 | 33,750 | 0 | 0 | 0 | 117,404 |
| Friday, April 29th, 2005 | 2004 | William J. Dawson Former Vice President, Finance Operations and Chief Financial Officer | 225,000 | 0 | 0 | 0 | 0 | 225,000 |
| Friday, April 29th, 2005 | 2003 | William J. Dawson Former Vice President, Finance Operations and Chief Financial Officer | 225,000 | 45,000 | 0 | 0 | 0 | 270,000 |
| Friday, April 29th, 2005 | 2004 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 250,000 | 100,000 | 0 | 0 | 0 | 350,000 |
| Friday, April 29th, 2005 | 2003 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 104,166 | 0 | 0 | 0 | 0 | 104,166 |
| Friday, April 29th, 2005 | 2002 | Daniel Levitt, M.D., Ph.D. Vice President and Chief Medical Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Friday, April 29th, 2005 | 2004 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 212,500 | 85,000 | 0 | 0 | 0 | 297,500 |
| Friday, April 29th, 2005 | 2003 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| Friday, April 29th, 2005 | 2004 | Dino Dina, M.D. President and Chief Executive Officer and Director | 325,000 | 130,000 | 0 | 0 | 0 | 455,000 |
| Friday, April 29th, 2005 | 2003 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 120,000 | 0 | 0 | 0 | 420,000 |
| Friday, April 29th, 2005 | 2002 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 180,000 | 54,000 | 0 | 0 | 0 | 234,000 |
| Friday, April 29th, 2005 | 2004 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 240,000 | 96,000 | 0 | 0 | 0 | 336,000 |
| Friday, April 29th, 2005 | 2003 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 218,500 | 65,550 | 0 | 0 | 0 | 284,050 |
| Thursday, April 29th, 2004 | 2002 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 105,000 | 0 | 0 | 0 | 405,000 |
| Thursday, April 29th, 2004 | 2003 | Dino Dina, M.D. President and Chief Executive Officer and Director | 300,000 | 120,000 | 0 | 0 | 0 | 420,000 |
| Thursday, April 29th, 2004 | 2002 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 180,000 | 54,000 | 0 | 0 | 0 | 234,000 |
| Thursday, April 29th, 2004 | 2001 | Dino Dina, M.D. President and Chief Executive Officer and Director | 275,000 | 82,500 | 0 | 0 | 0 | 357,500 |
| Thursday, April 29th, 2004 | 2003 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 218,500 | 65,550 | 0 | 0 | 0 | 284,050 |
| Thursday, April 29th, 2004 | 2002 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 210,000 | 63,000 | 0 | 0 | 0 | 273,000 |
| Thursday, April 29th, 2004 | 2001 | Robert Coffman, Ph.D. Vice President and Chief Scientific Officer | 200,000 | 60,000 | 0 | 0 | 0 | 260,000 |
| Thursday, April 29th, 2004 | 2003 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| Thursday, April 29th, 2004 | 2002 | William J. Dawson Vice President, Finance Operations and Chief Financial Officer | 83,654 | 33,750 | 0 | 0 | 0 | 117,404 |
| Thursday, April 29th, 2004 | 2003 | William J. Dawson Vice President, Finance Operations and Chief Financial Officer | 225,000 | 45,000 | 0 | 0 | 0 | 270,000 |
| Thursday, April 29th, 2004 | 2001 | William J. Dawson Vice President, Finance Operations and Chief Financial Officer | 0 | 0 | 0 | 0 | 0 | 0 |
| Thursday, April 29th, 2004 | 2001 | Stephen F. Tuck, Ph.D. Vice President, Biopharmaceutical Development | 165,000 | 49,500 | 0 | 0 | 0 | 214,500 |
| Thursday, April 29th, 2004 | 2003 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 192,600 | 57,780 | 0 | 0 | 0 | 250,380 |
| Thursday, April 29th, 2004 | 2002 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 180,000 | 54,000 | 0 | 0 | 0 | 234,000 |
| Thursday, April 29th, 2004 | 2001 | Gary A. Van Nest, Ph.D. Vice President, Preclinical Research | 165,000 | 41,250 | 0 | 0 | 0 | 206,250 |
